XML 22 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1

RESTRUCTURING

9 Months Ended

Dec. 28, 2024

Restructuring and Related Activities [Abstract]

RESTRUCTURING

5. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges of approximately $85.0 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and nine months ended December 28, 2024, the Company incurred $1.9 million and $6.0 million, respectively, of restructuring and restructuring related costs under this program. During the three and nine months ended December 30, 2023, the Company incurred $2.6 million and $6.8 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $83.0 million through December 28, 2024.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. In the three and nine months ended December 28, 2024, the Company incurred $3.1 million and $12.5 million of expenses, respectively, of restructuring and restructuring related costs in connection with these portfolio rationalization initiatives. In both the three and nine months ended December 30, 2023, the Company incurred $7.8 million of restructuring and related costs related to these portfolio rationalization initiatives.

The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives and the 2020 Program for the nine months ended December 28, 2024, which relates to employee severance, other employee costs, inventory reserves and lease termination fees:

(In thousands)						Portfolio Rationalization						2020 Program												Total
Balance at March 30, 2024						$	11,309					$	485											$	11,794
Costs incurred, net of reversals						12,296						633												12,929
Payments						(10,837)						(652)												(11,489)
Non-cash adjustments						(8,616)						—												(8,616)
Balance at December 28, 2024						$	4,152					$	466											$	4,618

The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:

			Three Months Ended												Nine Months Ended
(In thousands)			December 28, 2024						December 30, 2023						December 28, 2024						December 30, 2023
Cost of goods sold			$	3,027					$	7,065					$	11,158					$	7,329
Research and development			(4)						343						(16)						343
Selling, general and administrative expenses			492						560						1,787						371
Total			$	3,515					$	7,968					$	12,929					$	8,043

As of December 28, 2024, the Company had a restructuring liability of $4.6 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The tables below present restructuring and restructuring related costs by reportable segment:

Restructuring costs			Three Months Ended												Nine Months Ended
(In thousands)			December 28, 2024						December 30, 2023						December 28, 2024						December 30, 2023
Plasma			$	77					$	33					$	284					$	(164)
Blood Center			685						4,546						4,241						4,546
Hospital			774						2,503						1,404						2,745
Corporate			1,979						886						7,000						916
Total			$	3,515					$	7,968					$	12,929					$	8,043
Restructuring related costs			Three Months Ended												Nine Months Ended
(In thousands)			December 28, 2024						December 30, 2023						December 28, 2024						December 30, 2023
Plasma			$	37					$	72					$	263					$	315
Blood Center			31						93						120						166
Hospital			(68)						251						40						398
Corporate			1,468						1,987						5,134						5,675
Total			$	1,468					$	2,403					$	5,557					$	6,554
Total restructuring and restructuring related costs			$	4,983					$	10,371					$	18,486					$	14,597

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4.e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/420/tableOfContent

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration